mage-a3 peptide
Biologicalexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00090493)
Timeline
Indications
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mage-3 peptide
- mage-3 peptide
- mage-a3 peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00960752 | Phase 2 | May 1, 2010 | University of Texas at Houston |
| NCT00254397 | Phase 2 | Nov 1, 2005 | University of Texas at Houston |
| NCT00257738 | Phase 1 | Nov 1, 2005 | National Institute of Dental and Craniofacial Research (NIDCR), University of Maryland |
| NCT00090493 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2004 | Hoosier Cancer Research Network, Myeloma Institute for Research & Therapy |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 1 | 2005 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Myeloma Institute for Research & Therapy | Academic/Hospital | 1 | 0 | 1 | 2004 |
| National Institute of Dental and Craniofacial Research (NIDCR) | Government | 1 | 0 | 1 | 2005 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2005 |
5 organizations
Page 1 / 1